COCP vs. ZIVO, VTGN, CLLS, TARA, SCLX, INZY, AVTX, MGX, AVTE, and ABOS
Should you be buying Cocrystal Pharma stock or one of its competitors? The main competitors of Cocrystal Pharma include ZIVO Bioscience (ZIVO), Vistagen Therapeutics (VTGN), Cellectis (CLLS), Protara Therapeutics (TARA), Scilex (SCLX), Inozyme Pharma (INZY), Avalo Therapeutics (AVTX), Metagenomi (MGX), Aerovate Therapeutics (AVTE), and Acumen Pharmaceuticals (ABOS). These companies are all part of the "pharmaceutical products" industry.
Cocrystal Pharma vs.
ZIVO Bioscience (NASDAQ:ZIVO) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings, community ranking and analyst recommendations.
Cocrystal Pharma has a consensus target price of $7.00, suggesting a potential upside of 298.86%. Given Cocrystal Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Cocrystal Pharma is more favorable than ZIVO Bioscience.
ZIVO Bioscience received 75 more outperform votes than Cocrystal Pharma when rated by MarketBeat users. However, 77.42% of users gave Cocrystal Pharma an outperform vote while only 60.74% of users gave ZIVO Bioscience an outperform vote.
12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 21.5% of ZIVO Bioscience shares are held by insiders. Comparatively, 25.6% of Cocrystal Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Cocrystal Pharma had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for Cocrystal Pharma and 1 mentions for ZIVO Bioscience. Cocrystal Pharma's average media sentiment score of 1.44 beat ZIVO Bioscience's score of 0.00 indicating that Cocrystal Pharma is being referred to more favorably in the news media.
ZIVO Bioscience's return on equity of 0.00% beat Cocrystal Pharma's return on equity.
ZIVO Bioscience has higher revenue and earnings than Cocrystal Pharma. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.
ZIVO Bioscience has a beta of 0.12, meaning that its stock price is 88% less volatile than the S&P 500. Comparatively, Cocrystal Pharma has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500.
Summary
Cocrystal Pharma beats ZIVO Bioscience on 11 of the 16 factors compared between the two stocks.
Get Cocrystal Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for COCP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cocrystal Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:COCP) was last updated on 3/4/2025 by MarketBeat.com Staff
